Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders – StreetInsider.com

Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders – StreetInsider.com
Source: Google NewsPublished on 2021-02-17